J&J no longer co-promoting Capoten
Executive Summary
Bristol-Myers Squibb and Johnson & Johnson's McNeil Pharmaceutical unit agree to discontinue, effective June 21, the co-promotion arrangement covering the ACE inhibitor product. McNeil's 450-rep sales force had been promoting Capoten to primary care physicians since January 1988. Bristol-Myers, which acquired Squibb in 1989, explained that the merger "now enables us to use our own greatly expanded sales force to sell Capoten in the U.S."
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.